4//SEC Filing
EVNIN LUKE 4
Accession 0001134657-26-000004
CIK 0001785530other
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 5:09 PM ET
Size
11.5 KB
Accession
0001134657-26-000004
Insider Transaction Report
Form 4
EVNIN LUKE
Director
Transactions
- Sale
Common Stock
[F1][F2][F3][F4][F5]2026-01-08$0.63/sh−7,716$4,861→ 2,393,527 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F6][F7][F4][F8]2026-01-09$0.61/sh−24,678$15,054→ 2,368,849 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F9][F10][F4][F11]2026-01-12$0.57/sh−58,980$33,619→ 2,309,869 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5608 to $0.606 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 247,458 by AM LLC, 1,562,439 by BV 2014, 104,212 by BV 2014(B), 53,772 by AM BV2014 and 341,988 by MPM OIF.
- [F2]The shares were sold as follows: 825 by MPM Asset Management LLC ("AM LLC"), 5,215 by MPM BioVentures 2014, L.P. ("BV 2014"), 348 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 180 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,148 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6243 to $0.6368 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F5]The shares are held as follows: 256,407 by AM LLC, 1,618,978 by BV 2014, 107,983 by BV 2014(B), 55,720 by AM BV2014 and 354,439 by MPM OIF.
- [F6]The shares were sold as follows: 2,640 by AM LLC, 16,678 by BV 2014, 1,112 by BV 2014(B), 575 by AM BV2014 and 3,673 by MPM OIF.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6019 to $0.6583 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 253,767 by AM LLC, 1,602,300 by BV 2014, 106,871 by BV 2014(B), 55,145 by AM BV2014 and 350,766 by MPM OIF.
- [F9]The shares were sold as follows: 6,309 by AM LLC, 39,861 by BV 2014, 2,659 by BV 2014(B), 1,373 by AM BV2014 and 8,778 by MPM OIF.
Signature
/s/ Luke Evnin|2026-01-12
Documents
Issuer
Werewolf Therapeutics, Inc.
CIK 0001785530
Entity typeother
Related Parties
1- filerCIK 0001134657
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 5:09 PM ET
- Size
- 11.5 KB